Back to Library
KPV
Research Use OnlyPreclinical research with limited clinical data; under FDA PCAC review for compounding. Not FDA approved.
KPV Tripeptide
Description
An anti-inflammatory tripeptide derived from alpha-MSH. Potent immunomodulatory properties help reduce inflammation and support gut health.
Dose:500 mcg
Frequency:5 days on, 2 days off (8 weeks on/off cycle)
Administration Method: SQ
CategoryImmunity
Half-LifeShort (estimated minutes); not well characterized for the tripeptide.
Overview
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH). It retains the anti-inflammatory properties of α-MSH without causing pigmentation changes and is studied for gut inflammation, skin conditions, and immune modulation.
Mechanism of Action
KPV inhibits activation of NF-κB, a master transcription factor regulating immune responses and inflammation. By suppressing NF-κB it reduces production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
Benefits
- •Anti-inflammatory
- •Gut health support
- •Immune modulation
- •Tissue healing
Reported Side Effects
- •Limited human safety data
- •Possible injection site reactions